Who makes DSP-5423P Placebo-to-Flex?

DSP-5423P Placebo-to-Flex is developed by Sumitomo Pharma Co., Ltd..

What development phase is DSP-5423P Placebo-to-Flex in?

DSP-5423P Placebo-to-Flex is in Phase 3.

Last reviewed 2026-05-14 · How we verify

DSP-5423P Placebo-to-Flex

Sumitomo Pharma Co., Ltd. · Phase 3 active Small molecule

DSP-5423P Placebo-to-Flex's mechanism of action is currently unknown.

At a glance

Generic name	DSP-5423P Placebo-to-Flex
Sponsor	Sumitomo Pharma Co., Ltd.
Modality	Small molecule
Phase	Phase 3

Mechanism of action

There is limited information available on DSP-5423P Placebo-to-Flex's mechanism of action, and it is not well understood at this time.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Confirmatory Study of DSP-5423P in Patients With Schizophrenia (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

DSP-5423P Placebo-to-Flex CI brief — competitive landscape report
DSP-5423P Placebo-to-Flex updates RSS · CI watch RSS
Sumitomo Pharma Co., Ltd. portfolio CI